Premium
Commentary: BMI and the need for adalimumab dose escalation in Crohn's disease – authors’ reply
Author(s) -
Bultman E.,
Woude C. J.
Publication year - 2012
Publication title -
alimentary pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.308
H-Index - 177
eISSN - 1365-2036
pISSN - 0269-2813
DOI - 10.1111/j.1365-2036.2012.05045.x
Subject(s) - medicine , adalimumab , infliximab , declaration , de escalation , confounding , adverse effect , family medicine , disease , political science , law